SCHEMBL1264282

SCHEMBL1264282

NNC(=O)c1ccc(N)cc1NN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
GFER P55789 2/20 0.47
MAPT P10636 9/20 0.46
KDM4E B2RXH2 6/20 0.46
TDP1 Q9NUW8 5/20 0.44
GAA P10253 5/20 0.41
CYP3A4 P08684 2/20 0.41
ESR2 Q92731 1/20 0.41
PTPN1 P18031 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MITF O75030 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
KLKB1 P03952 1/20 0.40
POLB P06746 2/20 0.39
ALOX5 P09917 1/20 0.38
JAK2 O60674 1/20 0.37
TYK2 P29597 1/20 0.37
THRB P10828 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436632 0.82 ALDH1A1 (0.52) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL8759303 0.80 ALDH1A1 (0.50) ALDH1A1GFERMAPTKDM4ETDP1
Water SCHEMBL1648598 0.80 ALDH1A1 (0.50) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL1264279 0.78 ALDH1A1 (0.69) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL21408389 0.77 MAPT (0.55) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL31161439 0.77 ALDH1A1 (0.55) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL19823877 0.77 MAPT (0.70) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL2700198 0.76 MAPT (0.59) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL9318885 0.74 ALDH1A1 (0.45) ALDH1A1GFERMAPTKDM4ETDP1
SCHEMBL5679153 0.73 ALDH1A1 (0.67) ALDH1A1GFERMAPTKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 WO claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 US claimed
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2009-12-10 US claimed
EP-2041108-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS Antibe Therapeutics Inc. (US) 2009-04-01 EP claimed
WO-2008009118-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2008-01-24 WO claimed
US-7186753-B1 Pharmaceutical compounds NICOX S.A. (FR) 2007-03-06 US claimed
JP-2003515526-A 2003-05-07 JP claimed
EP-1252133-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-10-30 EP claimed
EP-1192129-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-04-03 EP claimed
WO-2001012584-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2001-02-22 WO claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
CN-111808135-A Functionally modified oligonucleotides and subunits thereof 萨勒普塔医疗公司 2020-10-23 CN disclosed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP disclosed
US-8314140-B2 4-hydroxythiobenzamide derivatives of drugs ANTIBE THERAPEUTICS INC. (CA) 2012-11-20 US disclosed
US-5001115-A Prodrugs of biologically active hydroxyaromatic compounds UNIVERSITY OF FLORIDA (US) 1991-03-19 US disclosed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS HRH4, HRH2, HNMT ALDH1A1 319/4885GFER 1016/4885MAPT 2457/4885
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 ALDH1A1 204/4885GFER 117/4885MAPT 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.